AMANDA ZUBER: Open Payments
NPI 1215493747 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$393 in 14 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $420 · 2025 $393
Food & beverage: $393
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $96 |
| Octapharma USA, Inc. | 1 | $42 |
| Lundbeck LLC | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Janssen Biotech, Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $31 |
| TG Therapeutics, Inc. | 1 | $31 |
| SOBI, INC | 1 | $31 |
| PFIZER INC. | 1 | $29 |
| Alexion Pharmaceuticals, Inc. | 1 | $25 |
Products named: NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), VYEPTI, SAPHNELO, TREMFYA, Ocrevus Zunovo, BRIUMVI, ULTOMIRIS.
Industry payments across CO — which companies pay providers there.
